MTOR and breast cancer: In 2017, Sonia Sharma et al. synthesized 4-chlorofascaplysin (74, Scheme 3; a marine sponge alkaloid fascaplysin analogue) and found it to be cytotoxic to breast cancer cells in vitro (IC50 = 0.3 μM) and to inhibit PI3K/AKt/mTOR in vitro and in vivo [99].